LGND - Ligand Pharmaceuticals Inc Stock Price, Fair Value and News

84.10USD-3.18 (-3.64%)Market Closed

Market Summary

USD84.10-3.18

Market Closed

-3.64%

LGND Alerts

Big fall in Revenue (Y/Y)

Big jump in Earnings (Y/Y)

LGND Stock Price

View Fullscreen

LGND RSI Chart

LGND Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

15.68

Price/Sales (Trailing)

12.77

EV/EBITDA

9.25

Price/Free Cashflow

45.57

LGND Price/Sales (Trailing)

LGND Profitability

EBT Margin

102.75%

Return on Equity

11.95%

Return on Assets

10.54%

Free Cashflow Yield

2.19%

LGND Fundamentals

LGND Revenue

Revenue (TTM)

118.3M

Rev. Growth (Yr)

-29.56%

Rev. Growth (Qtr)

10.24%

LGND Earnings

Earnings (TTM)

96.3M

Earnings Growth (Yr)

105.34%

Earnings Growth (Qtr)

373.6%

Breaking Down LGND Revenue

Last 7 days

15.5%

Last 30 days

3.4%

Last 90 days

18.5%

Trailing 12 Months

11.2%

How does LGND drawdown profile look like?

LGND Financial Health

Current Ratio

20.7

LGND Investor Care

Shares Dilution (1Y)

4.00%

Diluted EPS (TTM)

5.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	118.3M	0	0	0
2023	203.7M	179.9M	153.6M	131.3M
2022	231.5M	202.7M	202.3M	196.2M
2021	199.8M	237.3M	255.1M	241.5M
2020	110.0M	126.4M	143.4M	186.4M
2019	238.8M	173.7M	152.9M	120.3M
2018	251.5M	251.5M	251.5M	251.5M
2017	135.5M	206.0M	230.0M	251.5M
2016	87.0M	88.1M	92.0M	109.0M
2015	63.2M	71.0M	73.7M	71.9M
2014	53.3M	54.3M	56.3M	64.5M
2013	37.4M	41.2M	47.9M	49.0M
2012	31.8M	30.1M	30.7M	31.4M
2011	21.5M	23.1M	21.0M	30.0M
2010	0	33.8M	28.7M	23.5M
2009	0	0	0	38.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ligand Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 30, 2024	aryeh jason	acquired	125,834	52.3	2,406	-
Apr 24, 2024	kozarich john w	acquired	113,840	39.35	2,893	-
Mar 25, 2024	davis todd c	acquired	919,147	57.3929	16,015	chief executive officer
Mar 05, 2024	aryeh jason	acquired	113,840	39.35	2,893	-
Mar 05, 2024	sabba stephen l	acquired	-	-	2,893	-
Mar 05, 2024	sabba stephen l	sold	-140,650	74.3	-1,893	-
Feb 28, 2024	espinoza octavio	sold	-12,384	88.46	-140	chief financial officer
Feb 28, 2024	espinoza octavio	acquired	71,564	56.6173	1,264	chief financial officer
Feb 27, 2024	davis todd c	acquired	-	-	32,436	chief executive officer
Feb 27, 2024	reardon andrew	acquired	-	-	7,208	chief legal officer &

Which funds bought or sold LGND recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	PRINCIPAL SECURITIES, INC.	reduced	-68.27	-36,026	17,325	-%
May 10, 2024	Campbell & CO Investment Adviser LLC	reduced	-37.2	-193,406	348,029	0.03%
May 10, 2024	Hillsdale Investment Management Inc.	added	8.43	325,623	3,291,840	0.26%
May 10, 2024	JUPITER ASSET MANAGEMENT LTD	unchanged	-	9,669	420,691	-%
May 10, 2024	CITIGROUP INC	added	6.56	80,559	969,452	-%
May 10, 2024	Covestor Ltd	added	116	1,000	1,000	-%
May 10, 2024	GROUP ONE TRADING, L.P.	sold off	-100	-65,421	-	-%
May 10, 2024	PNC Financial Services Group, Inc.	added	20.16	30,211	161,623	-%
May 10, 2024	Pacer Advisors, Inc.	sold off	-100	-23,263,400	-	-%
May 10, 2024	CIBC Private Wealth Group, LLC	new	-	11,776	11,776	-%

Are Funds Buying or Selling LGND?

Are funds buying LGND calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LGND

No. of Funds

Unveiling Ligand Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	macquarie group ltd	5.66%	987,248	SC 13G
Feb 13, 2024	janus henderson group plc	7.7%	1,343,154	SC 13G/A
Feb 13, 2024	vanguard group inc	10.76%	1,876,514	SC 13G/A
Feb 12, 2024	goldman sachs group inc	6.8%	1,181,931	SC 13G
Jan 22, 2024	blackrock inc.	17.0%	2,962,094	SC 13G/A
Feb 10, 2023	janus henderson group plc	7.4%	1,255,273	SC 13G/A
Feb 09, 2023	william blair investment management, llc	0.8%	141,128	SC 13G/A
Feb 09, 2023	vanguard group inc	10.91%	1,843,115	SC 13G/A
Feb 06, 2023	state street corp	3.85%	649,914	SC 13G/A
Jan 26, 2023	blackrock inc.	16.5%	2,789,479	SC 13G/A

Recent SEC filings of Ligand Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	144	Notice of Insider Sale Intent
May 13, 2024	4	Insider Trading
May 09, 2024	144	Notice of Insider Sale Intent
May 09, 2024	144	Notice of Insider Sale Intent
May 09, 2024	DEFA14A	DEFA14A
May 08, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
May 02, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading

Peers (Alternatives to Ligand Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Ligand Pharmaceuticals Inc News

Latest updates

Ligand Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	10.2%	31.00	28.00	33.00	26.00	44.00	50.00	59.00	50.00	37.00	56.00	60.00	79.00	47.00	70.00	42.00	41.00	33.00	27.00	25.00	25.00	43.00
Operating Expenses	-11.0%	28.00	31.00	32.00	28.00	30.00	70.00	47.00	41.00	34.00	41.00	35.00	25.00	37.00	76.00	38.00	34.00	29.00	37.00	30.00	29.00	30.00
S&GA Expenses	-100.0%	-	16.00	15.00	11.00	11.00	31.00	15.00	12.00	12.00	13.00	11.00	12.00	11.00	26.00	15.00	10.00	9.00	10.00	10.00	11.00	11.00
R&D Expenses	8.8%	6.00	5.00	6.00	7.00	7.00	9.00	9.00	8.00	9.00	8.00	7.00	7.00	9.00	3.00	13.00	13.00	12.00	19.00	14.00	12.00	11.00
EBITDA Margin	73.8%	1.33*	0.77*	0.72*	0.78*	0.73*	0.46*	0.44*	0.47*	0.54*	0.59*	0.56*	0.46*	-	-	-	-	-	-	-	-	-
Interest Expenses	7.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	4.00	4.00	5.00	6.00	6.00	6.00	6.00	9.00	9.00	9.00	9.00	9.00
Income Taxes	2603.0%	27.00	-1.09	-1.87	1.00	12.00	39.00	3.00	-3.94	4.00	4.00	2.00	3.00	-12.34	-2.39	-4.91	6.00	-6.28	-0.81	-4.62	-3.61	176
Earnings Before Taxes	563.5%	113	17.00	-12.14	3.00	56.00	24.00	12.00	9.00	-9.14	18.00	15.00	33.00	6.00	15.00	-11.61	28.00	-30.41	-8.18	-19.87	-18.03	843
EBT Margin	112.0%	1.03*	0.48*	0.46*	0.53*	0.49*	0.18*	0.15*	0.16*	0.25*	0.30*	0.27*	0.18*	-	-	-	-	-	-	-	-	-
Net Income	373.6%	86.00	18.00	-10.27	2.00	42.00	-17.48	0.00	-0.89	-15.38	-5.42	14.00	31.00	18.00	6.00	-6.70	22.00	-24.13	-7.36	-15.25	-14.42	666
Net Income Margin	105.0%	0.81*	0.40*	0.11*	0.15*	0.12*	-0.17*	-0.11*	-0.04*	0.10*	0.24*	0.27*	0.20*	-	-	-	-	-	-	-	-	-
Free Cashflow	143.6%	19.00	8.00	7.00	-0.28	32.00	51.00	16.00	5.00	47.00	25.00	18.00	19.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	16.1%	914	787	769	758	811	763	1,051	1,076	1,105	1,298	1,274	1,256	1,295	1,362	1,247	1,243	1,186	1,495	1,547	1,802	1,914
Current Assets	55.4%	369	237	254	277	328	264	220	244	276	465	432	411	437	501	858	864	831	1,124	1,183	1,442	1,568
Cash Equivalents	118.2%	50.00	23.00	19.00	28.00	89.00	45.00	4.00	5.00	15.00	20.00	23.00	22.00	32.00	48.00	457	116	118	72.00	226	274	107
Inventory	-11.0%	21.00	24.00	25.00	27.00	14.00	13.00	22.00	25.00	26.00	27.00	33.00	40.00	37.00	26.00	13.00	4.00	7.00	7.00	7.00	10.00	12.00
Net PPE	-3.0%	15.00	16.00	16.00	11.00	12.00	12.00	33.00	31.00	25.00	13.00	19.00	18.00	17.00	13.00	7.00	8.00	7.00	7.00	6.00	6.00	6.00
Goodwill	1.8%	105	103	2.00	106	106	106	-	181	181	-	190	191	191	190	82.00	103	9.00	95.00	94.00	88.00	87.00
Liabilities	24.4%	107	86.00	101	93.00	165	165	234	274	312	476	462	470	549	653	550	548	524	728	697	760	834
Current Liabilities	6.2%	18.00	17.00	16.00	29.00	99.00	99.00	135	168	43.00	42.00	36.00	52.00	96.00	100	42.00	29.00	20.00	17.00	36.00	109	187
Long Term Debt	-	-	-	-	-	-	-	-	-	177	321	317	315	352	442	455	450	444	639	632	624	617
LT Debt, Current	-	-	-	-	-	77.00	77.00	77.00	115	-	-	-	-	-	-	-	-	-	-	-	27.00	27.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	177	321	317	315	352	442	455	450	444	639	632	624	617
Shareholder's Equity	15.1%	807	701	668	665	646	597	816	802	793	821	812	787	746	710	698	695	662	767	851	1,041	1,080
Retained Earnings	17.1%	589	503	485	495	493	451	468	468	469	449	455	441	410	392	386	393	371	400	407	423	437
Additional Paid-In Capital	9.8%	218	199	184	171	154	148	349	335	325	373	358	347	337	318	313	304	296	367	445	619	643
Shares Outstanding	2.1%	18.00	18.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	900	-	-	-	1,000	-	-	-	1,800	-	-	-	1,200	-	-	-	1,800	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	132.3%	18,732	8,065	7,646	-82.00	33,948	53,472	20,489	11,878	52,011	27,642	20,025	20,377	10,754	537	12,745	24,382	16,922	-7,339	-6,197	-61,058	45,258
Share Based Compensation	28.2%	7,334	5,721	6,884	7,207	5,931	29,145	12,597	9,499	9,044	10,408	9,754	10,216	8,405	9,975	7,740	7,359	5,653	6,300	6,297	6,571	5,347
Cashflow From Investing	63.3%	-3,775	-10,284	-19,503	7,556	10,549	-7,284	19,176	37,851	113,881	-35,713	-18,217	19,338	65,115	-382,202	332,071	-26,757	308,536	-63,179	169,517	265,803	94,777
Cashflow From Financing	129.2%	12,182	5,315	3,270	-67,757	-775	-5,298	-40,829	-59,442	-170,421	4,164	-385	-49,905	-91,635	-27,529	-3,706	-5.00	-279,305	-83,693	-211,312	-37,591	-152,576
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,711	-	-	73,287	84,250	181,188	33,717	151,585

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LGND Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues and other income:
Total revenues and other income	$ 30,978	$ 43,979
Operating costs and expenses:
Cost of Captisol	2,882	3,717
Amortization of intangibles	8,186	8,539
Research and development	5,971	6,663
General and administrative	10,951	10,855
Total operating costs and expenses	27,990	29,774
Operating income from continuing operations	2,988	14,205
Non-operating income and expenses:
Gain from short-term investments	110,772	39,533
Interest income	2,020	1,435
Interest expense	(141)	(240)
Gain on derivative instruments	196	0
Other non-operating income (expense), net	(2,388)	603
Total non-operating income and expenses, net	110,459	41,331
Income before income taxes from continuing operations	113,447	55,536
Income tax expense	(27,308)	(11,922)
Net income from continuing operations	86,139	43,614
Net loss from discontinued operations	0	(1,665)
Net income	$ 86,139	$ 41,949
Earnings per share
Basic net income from continuing operations per share (in USD per share)	$ 4.86	$ 2.56
Basic net loss from discontinued operations per share (in USD per share)	0	(0.10)
Basic net income per share (in USD per share)	$ 4.86	$ 2.46
Shares used in basic per share calculation (in shares)	17,732	17,063
Diluted net income from continuing operations per share (in USD per share)	$ 4.75	$ 2.43
Diluted net loss from discontinued operations per share (in USD per share)	0	(0.09)
Diluted net income per share (in USD per share)	$ 4.75	$ 2.33
Shares used in diluted per share calculation (in shares)	18,122	17,974
Royalties
Revenues and other income:
Total revenues and other income	$ 19,095	$ 17,647
Revenue from intangible royalty assets
Revenues and other income:
Total revenues and other income	18,357	17,154
Income from financial royalty assets
Revenues and other income:
Total revenues and other income	738	493
Captisol
Revenues and other income:
Total revenues and other income	9,212	10,622
Contract revenue and other income
Revenues and other income:
Total revenues and other income	$ 2,671	$ 15,710

LGND Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 50,093	$ 22,954
Short-term investments	260,500	147,355
Accounts receivable, net	28,435	32,917
Inventory	21,337	23,969
Income taxes receivable	0	6,395
Prepaid expenses	1,237	1,182
Other current assets	7,311	2,657
Total current assets	368,913	237,429
Deferred income taxes, net	0	214
Intangible assets, net	291,420	299,606
Goodwill	105,250	103,370
Long-term portion of financial royalty assets, net	65,710	62,291
Property and equipment, net	15,135	15,607
Operating lease right-of-use assets	6,028	6,062
Finance lease right-of-use assets	3,219	3,393
Equity method investment in Primrose Bio	10,469	12,595
Other investments	36,500	36,726
Other assets	11,225	9,923
Total assets	913,869	787,216
Current liabilities:
Accounts payable	1,893	2,427
Accrued liabilities	12,430	12,467
Income taxes payable	1,138	0
Deferred revenue	1,227	1,222
Current contingent liabilities	127	256
Current operating lease liabilities	1,000	403
Current finance lease liabilities	3	7
Total current liabilities	17,818	16,782
Long-term deferred revenue	3,065	1,444
Long-term contingent liabilities	2,888	2,942
Deferred income taxes, net	50,606	31,622
Long-term operating lease liabilities	5,191	5,755
Other long-term liabilities	27,780	27,758
Total liabilities	107,348	86,303
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 60,000 shares authorized; 17,924 and 17,556 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	18	18
Additional paid-in capital	218,258	198,696
Accumulated other comprehensive loss	(910)	(817)
Retained earnings	589,155	503,016
Total stockholders' equity	806,521	700,913
Total liabilities and stockholders' equity	$ 913,869	$ 787,216

About Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.

CEO	Mr. Todd C. Davis Ph.D.
WEBSITE	ligand.com
INDUSTRY	Biotechnology
EMPLOYEES	76

Ligand Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Ligand Pharmaceuticals Inc? What does LGND stand for in stocks?

LGND is the stock ticker symbol of Ligand Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ligand Pharmaceuticals Inc (LGND)?

As of Mon May 13 2024, market cap of Ligand Pharmaceuticals Inc is 1.51 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LGND stock?

You can check LGND's fair value in chart for subscribers.

What is the fair value of LGND stock?

You can check LGND's fair value in chart for subscribers. The fair value of Ligand Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ligand Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LGND so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ligand Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether LGND is over valued or under valued. Whether Ligand Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ligand Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LGND.

What is Ligand Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, LGND's PE ratio (Price to Earnings) is 15.68 and Price to Sales (PS) ratio is 12.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LGND PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ligand Pharmaceuticals Inc's stock?

In the past 10 years, Ligand Pharmaceuticals Inc has provided 0.026 (multiply by 100 for percentage) rate of return.